Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

DRUG3 trials

Sponsors

Ruijin Hospital, Second Affiliated Hospital of Xi'an Jiaotong University

Conditions

LymphomaLymphoma, B-CellRefractory B Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia

Phase 1

Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

Ruijin HospitalLymphoma

Start: 2018-01-01End: 2020-01-01Target: 10Updated: 2018-03-20

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

TerminatedNCT03593109

Second Affiliated Hospital of Xi'an Jiaotong UniversityLymphoma, B-Cell

Start: 2019-05-30End: 2021-05-01Updated: 2021-11-01

Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy in R/R Acute B Lymphoblastic Leukemia

WithdrawnNCT04094766

Second Affiliated Hospital of Xi'an Jiaotong UniversityRefractory B Acute Lymphoblastic Leukemia, Relapse B Acute Lymphoblastic Leukemia

Start: 2017-08-01End: 2020-08-30Updated: 2020-11-05